Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used

Transplantation

Volumn 87, Issue 2, 2009, Pages 217-221

  Bartsch, Kristina ^a   Al Ali, Haifa ^a   Reinhardt, Annette ^a   Franke, Christina ^a   Hudecek, Michael ^a   Kamprad, Manja ^a   Tschiedel, Sabine ^a   Cross, Michael ^a   Niederwieser, Dietger ^a   Gentilini, Chiara ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Allogeneic stem cell transplantation; FISH; Mesenchymal stem cells

Indexed keywords

5' NUCLEOTIDASE; ENDOGLIN; HERMES ANTIGEN; LEUKOCYTE ANTIGEN; THY 1 ANTIGEN; MYELOABLATIVE AGENT;

ADIPOCYTE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR SELECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELOABLATIVE CONDITIONING; OSTEOBLAST; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; ADULT STEM CELL; ALLOTRANSPLANTATION; CELL PROLIFERATION; CELL SEPARATION; COMPARATIVE STUDY; CULTURE TECHNIQUE; DRUG EFFECT; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MESENCHYMAL STEM CELL; METHODOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; TIME;

ADULT; ADULT STEM CELLS; BONE MARROW TRANSPLANTATION; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL SEPARATION; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; MYELOABLATIVE AGONISTS; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 59649091248     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181938998     Document Type: Article

References (15)

1. Owen M, Friedenstein AJ. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp 1988; 136: 42.
2. Dennis JE, Charbord P. Origin and differentiation of human and murine stroma. Stem Cells 2002; 20: 205.
3. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991; 78: 55.
4. Kögler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200: 123.
5. Tondreau T, Meuleman N, Delforge A, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: Proliferation, Oct4 expression, and plasticity. Stem Cells 2005; 23: 1105.
6. Di NM, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838.
7. Le BK, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439.
8. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine follwed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620.
9. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143.
10. Simmons PJ, Przepiorka D, Thomas ED, et al. Host origin of marrow stromal cells following allogeniec bone marrow transplantation. Nature 1987; 328: 429.
11. Dickhut A, Schwerdtfeger R, Kuklick L, et al. Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue. Ann Hematol 2005; 84: 722.
12. Rieger K, Marinets O, Fietz T, et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Haematol 2005; 33: 605.
13. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932.
14. Lee ST, Jang JH, Cheong JW, et al. Treatment of high-risk acute myelogenous leukaemia bymyeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002; 118: 1128.
15. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307.